Osteoprotegerin is secreted into the coronary circulation: A possible association with the renin-angiotensin system and cardiac hypertrophy

Hormone and Metabolic Research

Volumn 46, Issue 8, 2014, Pages 581-586

  Koyama, S ^a   Tsuruda, T ^a   Ideguchi, T ^a   Kawagoe, J ^a   Onitsuka, H ^a   Ishikawa, T ^a   Date, H ^a   Hatakeyama, K ^a   Asada, Y ^a   Kato, J ^b   Kitamura, K ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

angiotensin II; concentric hypertrophy; remodeling

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY SINUS; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PULMONARY ARTERY OCCLUSION PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD; CARDIOMEGALY; CORONARY BLOOD VESSEL; HEART MUSCLE; HEART VENTRICLE; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOMEGALY; CORONARY CIRCULATION; CORONARY SINUS; CORONARY VESSELS; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; OSTEOPROTEGERIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84904561661     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1375611     Document Type: Article

References (44)

1. Najjar S. S., Scuteri A., Lakatta E. G. Arterial aging: Is it an immutable cardiovascular risk factor? Hypertension: 2005; 46 454 462 (Pubitemid 41376818)
2. Ganau A., Devereux R. B., Roman M. J., de Simone G., Pickering T. G., Saba P. S., Vargiu P., Simongini I., Laragh J. H. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol: 1992; 19 1550 1558
3. Levy D., Anderson K. M., Savage D. D., Kannel W. B., Christiansen J. C., Castelli W. P. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The framingham heart study. Ann Intern Med: 1988; 108 7 13 (Pubitemid 18081162)
4. Sadoshima J., Izumo S. Molecular characterization of angiotensin ii-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the at1 receptor subtype. Circ Res: 1993; 73 413 423 (Pubitemid 23238726)
5. Heymes C., Silvestre J. S., Llorens-Cortes C., Chevalier B., Marotte F., Levy B. I., Swynghedauw B., Samuel J. L. Cardiac senescence is associated with enhanced expression of angiotensin ii receptor subtypes. Endocrinology: 1998; 139 2579 2587 (Pubitemid 28513788)
6. Dai D. F., Santana L. F., Vermulst M., Tomazela D. M., Emond M. J., MacCoss M. J., Gollahon K., Martin G. M., Loeb L. A., Ladiges W. C., Rabinovitch P. S. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation: 2009; 119 2789 2797
7. Wang M., Takagi G., Asai K., Resuello R. G., Natividad F. F., Vatner D. E., Vatner S. F., Lakatta E. G. Aging increases aortic mmp-2 activity and angiotensin ii in nonhuman primates. Hypertension: 2003; 41 1308 1316 (Pubitemid 36706082)
8. Basso N., Cini R., Pietrelli A., Ferder L., Terragno N. A., Inserra F. Protective effect of long-term angiotensin ii inhibition. Am J Physiol Heart Circ Physiol: 2007; 293 H1351 H1358 (Pubitemid 47367173)
9. Michel J. B., Heudes D., Michel O., Poitevin P., Philippe M., Scalbert E., Corman B., Levy B. I. Effect of chronic ang i-converting enzyme inhibition on aging processes. II. Large arteries. Am J Physiol: 1994; 267 R124 R135
10. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H. L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W. J. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell: 1997; 89 309 319 (Pubitemid 27199902)
11. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun: 1997; 234 137 142 (Pubitemid 27267548)
12. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to trance/rankl. Proc Natl Acad Sci USA: 1998; 95 3597 3602
13. Yasuda H., Shima N., Nakagawa N., Mochizuki S., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (ocif) and osteoprotegerin (opg): A mechanism by which opg/ocif inhibits osteoclastogenesis in vitro. Endocrinology: 1998; 139 1329 1337 (Pubitemid 28510154)
14. Schoppet M., Ruppert V., Hofbauer L. C., Henser S., Al-Fakhri N., Christ M., Pankuweit S., Maisch B. Tnf-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochem Biophys Res Commun: 2005; 338 1745 1750 (Pubitemid 41643085)
15. Simionescu A., Simionescu D. T., Vyavahare N. R. Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-β1: Role of myofibroblasts in vascular calcification. Am J Pathol: 2007; 171 116 123 (Pubitemid 47339232)
16. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., Chen Y. E. Pdgf induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett: 2002; 521 180 184 (Pubitemid 34628481)
17. Moran C. S., Cullen B., Campbell J. H., Golledge J. Interaction between angiotensin ii, osteoprotegerin, and peroxisome proliferator-activated receptor-γ in abdominal aortic aneurysm. J Vasc Res: 2008; 46 209 217
18. Mainini G., Incoronato M., Urso L., Scaffa C. Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women. Clin Exp Obstet Gynecol: 2011; 38 355 359
19. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., Willvonseder R. Metabolism ASGoNVoB. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone: 2003; 32 681 686 (Pubitemid 37303940)
20. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation: 2002; 106 1192 1194 (Pubitemid 34988634)
21. Omland T., Drazner M. H., Ueland T., Abedin M., Murphy S. A., Aukrust P., de Lemos J. A. Plasma osteoprotegerin levels in the general population: Relation to indices of left ventricular structure and function. Hypertension: 2007; 49 1392 1399
22. Ueland T., Yndestad A., Oie E., Florholmen G., Halvorsen B., Froland S. S., Simonsen S., Christensen G., Gullestad L., Aukrust P. Dysregulated osteoprotegerin/rank ligand/rank axis in clinical and experimental heart failure. Circulation: 2005; 111 2461 2468 (Pubitemid 40696134)
23. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., Squire I. B., Gullestad L., Bollerslev J., Dickstein K., Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol: 2004; 44 1970 1976 (Pubitemid 39473280)
24. Noheria A., Mosley T. H., Kullo I. J. Association of serum osteoprotegerin with left ventricular mass in african american adults with hypertension. Am J Hypertens: 2010; 23 767 774
25. World Medical Association World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. JAMA: 2013; 310 2191 2194
26. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., Yamagata K., Tomino Y., Yokoyama H., Hishida A. Revised equations for estimated gfr from serum creatinine in japan. Am J Kidney Dis: 2009; 53 982 992
27. Date H., Imamura T., Ideguchi T., Kawagoe J., Sumi T., Masuyama H., Onitsuka H., Ishikawa T., Nagoshi T., Eto T. Adiponectin produced in coronary circulation regulates coronary flow reserve in nondiabetic patients with angiographically normal coronary arteries. Clin Cardiol: 2006; 29 211 214
28. Yamaguchi M., Tsuruda T., Watanabe Y., Onitsuka H., Furukawa K., Ideguchi T., Kawagoe J., Ishikawa T., Kato J., Takenaga M., Kitamura K. Reduced fractional shortening of right ventricular outflow tract is associated with adverse outcomes in patients with left ventricular dysfunction. Cardiovasc Ultrasound: 2013; 11 19
29. Devereux R. B., Alonso D. R., Lutas E. M., Gottlieb G. J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol: 1986; 57 450 458 (Pubitemid 16119719)
30. Devereux R. B., Wachtell K., Gerdts E., Boman K., Nieminen M. S., Papademetriou V., Rokkedal J., Harris K., Aurup P., Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA: 2004; 292 2350 2356 (Pubitemid 39491919)
31. Sadler D. B., Aurigemma G. P., Williams D. W., Reda D. J., Materson B. J., Gottdiener J. S. Systolic function in hypertensive men with concentric remodeling. Hypertension: 1997; 30 777 781 (Pubitemid 27441101)
32. Roysland R., Masson S., Omland T., Milani V., Bjerre M., Flyvbjerg A., Di Tano G., Misuraca G., Maggioni A. P., Tognoni G., Tavazzi L., Latini R. Investigators G-H Prognostic value of osteoprotegerin in chronic heart failure: The gissi-hf trial. Am Heart J: 2010; 160 286 293
33. Ueland T., Dahl C. P., Kjekshus J., Hulthe J., Böhm M., Mach F., Goudev A., Lindberg M., Wikstrand J., Aukrust P., Gullestad L. Osteoprotegerin predicts progression of chronic heart failure: Results from corona. Circ Heart Fail: 2011; 4 145 152
34. Jaumdally R., Varma C., Macfadyen R. J., Lip G. Y. Coronary sinus blood sampling: An insight into local cardiac pathophysiology and treatment? Eur Heart J: 2007; 28 929 940 (Pubitemid 47343904)
35. Schoppet M., Preissner K. T., Hofbauer L. C. Rank ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol: 2002; 22 549 553 (Pubitemid 34408732)
36. Moran C. S., McCann M., Karan M., Norman P., Ketheesan N., Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation: 2005; 111 3119 3125 (Pubitemid 40847790)
37. Helske S., Kovanen P. T., Lindstedt K. A., Salmela K., Lommi J., Turto H., Werkkala K., Kupari M. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail: 2007; 9 357 363 (Pubitemid 46441975)
38. Browner W. S., Lui L. Y., Cummings S. R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab: 2001; 86 631 637 (Pubitemid 32207471)
39. Bharti A. C., Takada Y., Shishodia S., Aggarwal B. B. Evidence that receptor activator of nuclear factor (nf)-kappab ligand can suppress cell proliferation and induce apoptosis through activation of a nf-kappab-independent and traf6-dependent mechanism. J Biol Chem: 2004; 279 6065 6076 (Pubitemid 38220639)
40. Pritzker L. B., Scatena M., Giachelli C. M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell: 2004; 15 2834 2841 (Pubitemid 38691871)
41. Mangan S. H., Van Campenhout A., Rush C., Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res: 2007; 76 494 505 (Pubitemid 350007458)
42. Lawrie A., Waterman E., Southwood M., Evans D., Suntharalingam J., Francis S., Crossman D., Croucher P., Morrell N., Newman C. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol: 2008; 172 256 264
43. Candido R., Toffoli B., Corallini F., Bernardi S., Zella D., Voltan R., Grill V., Celeghini C., Fabris B. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res: 2010; 47 252 261
44. Bystrom C. E., Salameh W., Reitz R., Clarke N. J. Plasma renin activity by lc-ms/ms: Development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem: 2010; 56 1561 1569